FDA Approves Daraxonrasib for Pancreatic Cancer
Analysis based on 6 articles · First reported Aug 26, 2026 · Last updated Sep 11, 2026
The approval gives Revolution Medicines a first-in-class commercial product in a high-unmet-need oncology market, supporting revenue expectations and validating its KRAS-targeting platform for future indications. It also raises competitive pressure and investment interest across the KRAS and pancreatic cancer drug development space, while payers and patients focus on the roughly $39,800 monthly price.
The United States — Food and Drug Administration approved daraxonrasib, a first-of-its-kind daily pill for metastatic pancreatic cancer, sold by Revolution Medicines under the brand name Rasonque. The drug blocks mutated KRAS proteins that drive tumor growth in more than 90% of pancreatic cancer cases, an approach that had eluded drugmakers for decades. In a company-funded trial of 500 patients whose cancer had progressed after prior treatment, median overall survival nearly doubled to 13.2 months versus 6.7 months for chemotherapy, with milder side effects such as rash, diarrhea and fatigue. A one-month supply is priced at approximately $39,800. The FDA granted expedited approval more than six months ahead of its target date, following a Breakthrough Therapy designation in June 2025 and an expanded access program that has already provided the drug free of charge to more than 2,000 patients since May. The American Cancer Society estimates about 67,000 new US cases and more than 52,000 deaths from pancreatic cancer annually, with a five-year survival rate of roughly 12-13%. Researchers at Dana–Farber Cancer Institute, Fred Hutchinson Cancer Center and City of Hope welcomed the approval and expect the KRAS-targeting approach to spur trials in other tumor types, including lung cancer. Former senator Ben Sasse publicly described reduced pain while taking the drug, boosting public interest.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard